Literature DB >> 28256436

Parkinsonian-Pyramidal syndromes: A systematic review.

Christine Tranchant1, Meriam Koob2, Mathieu Anheim3.   

Abstract

INTRODUCTION: Parkinsonian-Pyramidal syndrome (PPS), defined as the combination of both pyramidal and parkinsonian signs is a concept that recently emerged. PPS may manifest itself in numerous neurodegenerative diseases, many of these being inherited. Their diagnosis is a major challenge for the clinical management, for the prognosis, for genetic counselling and, in a few cases, which should not be neglected, for specific treatment.
OBJECTIVE: Our objective is to provide a review of PPS and an algorithm in order to guide their diagnosis in clinical practice.
METHODS: We performed an exhaustive PubMed and OMIM research matching the following key words: "Parkinsonism and pyramidal signs" or "Parkinsonism and spasticity" or "pallido-pyramidal syndrome" or "Parkinsonism and spastic paraplegia". English publications from the last ten years were included.
RESULTS: We propose a pragmatic presentation based on several established classifications and we will distinguish inherited PPS found in complex hereditary spastic paraplegia, young onset parkinsonism, neurodegeneration with brain iron accumulation, primary familial brain calcifications, inborn errors of metabolism, and few rare others inherited neurodegenerative diseases, then non-inherited neurodegenerative PPS. We therefore suggest guidelines (based on age at onset, family history, associated clinical signs, brain MRI findings as well as certain laboratory investigations), for the diagnosis and the management of PPS. Many pathophysiological pathways may underlie PPS but the most frequent are those usually involved in both inherited Parkinson's disease and spastic paraplegia, i.e. mitochondrial pathway, vesicular trafficking including endosomal and lysosomal pathways as well as autophagy.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Juvenile parkinsonism; NBIA; Parkinsonism; Pyramidal signs; Spasticity

Mesh:

Year:  2017        PMID: 28256436     DOI: 10.1016/j.parkreldis.2017.02.025

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  8 in total

1.  Is Pallido-Pyramidal Syndrome Still a Useful Concept? Yes.

Authors:  Christine Tranchant
Journal:  Mov Disord Clin Pract       Date:  2019-10-14

2.  Is Pallido-Pyramidal Syndrome Still a Useful Concept? No.

Authors:  Hugo Morales-Briceño; Victor S C Fung
Journal:  Mov Disord Clin Pract       Date:  2019-10-14

3.  Novel SEPSECS Pathogenic Variants Featuring Unusual Phenotype of Complex Movement Disorder With Thin Corpus Callosum: A Case Report.

Authors:  Francesco Nicita; Lorena Travaglini; Francesco Bombelli; Michele Tosi; Stefano Pro; Enrico Bertini; Adele D'Amico
Journal:  Neurol Genet       Date:  2021-03-03

Review 4.  A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies.

Authors:  Philippe A Salles; James Liao; Umar Shuaib; Ignacio F Mata; Hubert H Fernandez
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

5.  Action Myoclonus and Seizure in Kufor-Rakeb Syndrome.

Authors:  Mohammad Rohani; Anthony E Lang; Farzad Sina; Elahe Elahi; Alfonso Fasano; John Hardy; Jose Bras; Afagh Alavi
Journal:  Mov Disord Clin Pract       Date:  2017-12-28

6.  Janus-faced spatacsin (SPG11): involvement in neurodevelopment and multisystem neurodegeneration.

Authors:  Tatyana Pozner; Martin Regensburger; Tobias Engelhorn; Jürgen Winkler; Beate Winner
Journal:  Brain       Date:  2020-08-01       Impact factor: 13.501

Review 7.  Genetic Dystonia-ataxia Syndromes: Clinical Spectrum, Diagnostic Approach, and Treatment Options.

Authors:  Malco Rossi; Bettina Balint; Patricio Millar Vernetti; Kailash P Bhatia; Marcelo Merello
Journal:  Mov Disord Clin Pract       Date:  2018-07-03

8.  Impaired proteasome activity and neurodegeneration with brain iron accumulation in FBXO7 defect.

Authors:  Marta Correa-Vela; Vincenzo Lupo; Marta Montpeyó; Paula Sancho; Anna Marcé-Grau; Jorge Hernández-Vara; Alejandra Darling; Alison Jenkins; Sandra Fernández-Rodríguez; Cristina Tello; Laura Ramírez-Jiménez; Belén Pérez; Ángel Sánchez-Montáñez; Alfons Macaya; María J Sobrido; Marta Martinez-Vicente; Belén Pérez-Dueñas; Carmen Espinós
Journal:  Ann Clin Transl Neurol       Date:  2020-08-06       Impact factor: 4.511

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.